Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18–25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016

ObjectiveDue to long lag time between infection/cancer diagnoses human papillomavirus (HPV) vaccination programs will deliver vaccine efficacy (VE) estimates against cancer end-points late. Cancer registry follow-up of population-based, randomised trial cohorts of vaccinated and unvaccinated women was undertaken for the estimation of VE against cervical intraepithelial neoplasia grade three and invasive cancer (CIN3+).MethodsWe report interim results with 98 561 person years of Finnish Cancer Registry -based follow-up of individually and/or cluster randomised cohorts of HPV-16/18 vaccinated and unvaccinated adolescent women enrolled in June 2003/2005, and between May 2004 and April 2005, respectively. The cohorts comprised 15 627 18- to 19-year-old unvaccinated women (NCT01393470), and 2 401 and 64 16- to 17-year-old HPV-16/18 vaccinated women participating the PATRICIA (NCT00122681) and HPV-012 (NCT00169494) trials, respectively. The age-aligned passive follow-up started 6 months after the clinical trials’ end.ResultsDuring the follow-up of 4.5 to 10 years post enrolment we identified 75 cases of cervical intraepithelial neoplasia grade 3 (CIN3) and 4 cases of invasive cervical cancer (ICC) in the unvaccinated cohort, and 4 CIN3 cases in the HPV-16/18 vaccinated women. Diagnostic blocks were available for HPV typing from 87% of the cases. CIN3+ lesions were detectable in 54 cases. HPV16 was found in 26 of 50 unvaccinated CIN3+ cases, and in 3 CIN3+ cases in the HPV-16/18 vaccinated women. The latter were all baseline positive for cervical HPV16 DNA. Baseline data was not available for the unvaccinated women. Intention-to-treat VE against any CIN3+ was 66% (95% CI 8, 88).ConclusionsTen years post vaccination the AS04-adjuvanted HPV-16/18 vaccine shows continued efficacy against CIN3+ irrespectively of HPV type. Vaccine efficacy was not observed in baseline HPV16 DNA positive subjects.Trial registration numberNCT01393470.

Download Full-text

Risk Factors for Subsequent Cervicovaginal Human Papillomavirus (HPV) Infection and the Protective Role of Antibodies to HPV‐16 Virus‐Like Particles

The Journal of Infectious Diseases ◽

10.1086/342972 ◽

2002 ◽

Vol 186 (6) ◽

pp. 737-742 ◽

Cited By ~ 114

Author(s):

Gloria Y. F. Ho ◽

Yevgeniy Studentsov ◽

Charles B. Hall ◽

Robert Bierman ◽

Leah Beardsley ◽

...

Keyword(s):

Risk Factors ◽

Human Papillomavirus ◽

Hpv Infection ◽

Protective Role ◽

Hpv 16 ◽

Virus Like Particles

Download Full-text

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00453-8 ◽

2021 ◽

Author(s):

Partha Basu ◽

Sylla G Malvi ◽

Smita Joshi ◽

Neerja Bhatla ◽

Richard Muwonge ◽

...

Keyword(s):

Cohort Study ◽

Human Papillomavirus ◽

Prospective Cohort Study ◽

Vaccine Efficacy ◽

Hpv Vaccine ◽

Prospective Cohort ◽

Hpv 16 ◽

Quadrivalent Hpv Vaccine

Download Full-text

Genotypes distribution of human papillomavirus in cervical samples of Ecuadorian women

Revista Brasileira de Epidemiologia ◽

10.1590/1980-5497201600010014 ◽

2016 ◽

Vol 19 (1) ◽

pp. 160-166 ◽

Cited By ~ 8

Author(s):

Gustavo David García Muentes ◽

Lindsay Karen García Rodríguez ◽

Ramiro Israel Burgos Galarraga ◽

Franklin Almeida Carpio ◽

Juan Carlos Ruiz Cabezas

Keyword(s):

Cervical Cancer ◽

Human Papillomavirus ◽

Cancer Screening ◽

Cervical Cancer Screening ◽

Gynecological Cancer ◽

Hpv Infection ◽

Multiple Infections ◽

Hpv 16 ◽

Hpv Dna ◽

Hpv 18

ABSTRACT: Introduction: Human papillomavirus (HPV) is considered a necessary causative agent for developing oropharyngeal, anal and cervical cancer. Among women in Ecuadorian population, cervical cancer ranks as the second most common gynecological cancer. Not many studies about HPV burden have been published in Ecuador, and genotypes distribution has not been established yet. The little data available suggest the presence of other genotypes different than 16 and 18. Objectives: In the present study, we attempt to estimate the prevalence of HPV 16, HPV 18 and other 35 genotypes among Ecuadorian women undergoing cervical cancer screening. The overall prevalence of HPV infection was also estimated. Methods: Routine cervical samples were analyzed using Linear Array(r) HPV Genotyping test (Roche). Results: A total of 1,581 cervical samples obtained from Ecuadorian women undergoing cervical cancer screening were included in this study. HPV DNA was detected in 689 cervical samples (43.58%). Of these samples, 604 (38.20%) were positive for a single HPV genotype, while another 85 (5.37%) samples were positive for multiple HPV types. Genotype 16 (5.50%) resulted in the most frequently detected type in both single and multiple infections. HPV 33 (4.55%) and HPV 11 (3.80%) occupied the second and the third place in frequency among all detected genotypes. Conclusions: Viral genotypes different from HPV 16 and HPV 18 are frequently detected among Ecuadorian women. The overall prevalence of HPV resulted higher than the one reported in other South American countries with a greater burden in the second and third decades of life.

Download Full-text

Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia

Sexual Health ◽

10.1071/sh07042 ◽

2007 ◽

Vol 4 (3) ◽

pp. 147 ◽

Cited By ~ 40

Author(s):

David G. Regan ◽

David J. Philp ◽

Jane S. Hocking ◽

Matthew G. Law

Keyword(s):

Human Papillomavirus ◽

Cost Effectiveness ◽

Hpv Infection ◽

Conclusive Evidence ◽

Effective Vaccine ◽

High Coverage ◽

Hpv 16 ◽

Highly Effective ◽

Catch Up ◽

The Impact

Background: Vaccines are now available to prevent the development of cervical cancer from genital human papillomavirus (HPV) infection. The decision to vaccinate depends on a vaccine’s cost-effectiveness. A rigorous cost-effectiveness model for vaccinated individuals is presented in a companion paper; this paper investigates the additional benefits the community might receive from herd immunity. Methods: A mathematical model was developed to estimate the impact of a prophylactic vaccine on transmission of HPV type 16 in Australia. The model was used to estimate the expected reduction in HPV incidence and prevalence as a result of vaccination, the time required to achieve these reductions, and the coverage required for elimination. The modelled population was stratified according to age, gender, level of sexual activity and HPV infection status using a differential equation formulation. Clinical trials show that the vaccine is highly effective at preventing persistent infection and pre-cancerous lesions. These trials do not, however, provide conclusive evidence that infection is prevented altogether. The possible modes of vaccine action were investigated to see how vaccination might change the conclusions. Results: The model predicts that vaccination of 80% of 12-year-old girls will eventually reduce HPV 16 prevalence by 60–100% in vaccinated and 7–31% in unvaccinated females. If 80% of boys are also vaccinated, reductions will be 74–100% in vaccinated and 86–96% in unvaccinated females. A campaign covering only 12-year-old girls would require 5–7 years to achieve 50% of the eventual reduction. With a catch-up campaign covering 13–26-year-olds, this delay would be reduced to only 2 years. Unrealistically high coverage in both sexes would be required to eliminate HPV 16 from the population. Under pessimistic assumptions about the duration of vaccine-conferred immunity, HPV 16 incidence is predicted to rise in some older age groups. Conclusions: Mass vaccination with a highly effective vaccine against HPV 16 has the potential to substantially reduce the incidence and prevalence of infection. Catch-up vaccination offers the potential to substantially reduce the delay before the benefits of vaccination are observed. A booster vaccination might be required to prevent an increase in incidence of infection in women over 25 years of age.

Download Full-text

Human Papillomavirus and Genital Disease in Men: What We Have Learned from the HIM Study

Acta Cytologica ◽

10.1159/000493737 ◽

2019 ◽

Vol 63 (2) ◽

pp. 109-117 ◽

Cited By ~ 3

Author(s):

Laura Sichero ◽

Anna R. Giuliano ◽

Luisa Lina Villa

Keyword(s):

Human Papillomavirus ◽

Natural History ◽

The United States ◽

Hpv Infection ◽

Clinical Consequences ◽

History Of ◽

Crucial Information ◽

Associated Risk Factors ◽

The Relationship ◽

Genital Disease

It is currently recognized that in addition to the major impact of human papillomavirus (HPV) infection in females, HPV causes considerable disease in men at the genitals, anal canal, and oropharynx. Specifically, genital HPV infections may progress to genital warts and penile carcinoma. Although studies concerning the natural history of HPV infections and associated neoplasias have mainly focused on women, during the last 2 decades considerable attention has been given in further understanding these infections in men. The HIM (HPV infection in men) Study, the only prospective multicenter study of male HPV natural history, consisted of a large prospective international cohort study in which men from Brazil, the United States, and Mexico were enrolled. The design and protocols of this study allowed unraveling crucial information regarding the relationship between HPV infection and clinical consequences in men, and associated risk factors at each of the anatomic sites where HPV is known to cause cancer in men.

Download Full-text

Human Papillomavirus (Hpv) Typing in Relation to ras Oncogene mRNA Expression in HPV-Associated Human Squamous Cervical Neoplasia

The International Journal of Biological Markers ◽

10.1177/172460080502000409 ◽

2005 ◽

Vol 20 (4) ◽

pp. 257-263 ◽

Cited By ~ 5

Author(s):

I.N. Mammas ◽

A. Zafiropoulos ◽

S. Sifakis ◽

G. Sourvinos ◽

D.A. Spandidos

Keyword(s):

Cervical Cancer ◽

Polymerase Chain Reaction ◽

Human Papillomavirus ◽

Hpv Infection ◽

Cervical Neoplasia ◽

Chain Reaction ◽

Hpv 16 ◽

Expression Levels ◽

Hpv Typing ◽

Polymerase Chain

Objective Human papillomavirus (HPV) has been identified as the principal etiologic agent for cervical cancer and its precursors. Different HPV types have been associated with different oncogenic potential. The purpose of this study was to evaluate the relationship between specific HPV type infection and expression pattern of the ras family oncogenes in different grades of HPV-associated human cervical neoplasia. Methods HPV typing was performed using polymerase chain reaction (PCR) in 31 HPV-positive human cervical specimens from patients with squamous intraepithelial lesions (SIL) or squamous cervical carcinoma (SCC). The mRNA expression levels of H-, K- and N-ras oncogenes were examined using the reverse transcriptase polymerase chain reaction (RT-PCR) technique. Statistical analyses were performed using SPSS software. Results Among patients with SCC, H-, K- and N-ras expression levels were higher in HPV 16/18-associated cases compared to HPV 16/18-unassociated samples (p=0.003, p=0.004 and p=0.0001, respectively). The expression levels for H-, K-and N-ras were significantly higher in SCC patients with multiple HPV infection compared with SCC patients with single HPV infection (p=0.009, p=0.01 and p=0.021, respectively). Among patients with SIL, no statistically significant relationship was found between ras expression and HPV status. Conclusion Our findings indicate the possible role of ras signaling interaction with “high-risk” HPV 16/18 and multiple HPV infection in cervical cancer development.

Download Full-text

Human Papillomavirus in Endometrial Adenocarcinomas: Infectious Agent or a Mere “Passenger”?

Infectious Diseases in Obstetrics and Gynecology ◽

10.1155/2007/60549 ◽

2007 ◽

Vol 2007 ◽

pp. 1-4 ◽

Cited By ~ 12

Author(s):

A. Giatromanolaki ◽

E. Sivridis ◽

D. Papazoglou ◽

M. I. Koukourakis ◽

E. Maltezos

Keyword(s):

Human Papillomavirus ◽

Endometrial Adenocarcinoma ◽

Myometrial Invasion ◽

Infectious Agent ◽

Hpv Infection ◽

Squamous Differentiation ◽

Cytological Evidence ◽

Hpv 16 ◽

Polymerase Chain ◽

Hpv 18

Aims. To investigate the possible association of human papillomavirus (HPV) with endometrial hyperplasias and neoplasia. Does HPV play any role in the initiation or prognosis of endometrial adenocarcinomas?Methods. Twenty-five endometrial adenocarcinomas of the endometrioid cell type, with and without squamous differentiation, and twenty-four endometrial hyperplasias of various forms (simple, complex, and atypical) were analyzed for the presence of type 16 and 18 HPV by the polymerase chain reaction (PCR). The results were related to histopathological features of the tumour, and the patients' age, and prognosis.Results. Six of 25 endometrial adenocarcinomas were HPV 16-positive (24%), and 5 of 25 (20%) were HPV 18-positive. Simple endometrial hyperplasias was associated somewhat more commonly with HPV 16 and 18 (2/8 and 1/8 cases, resp) than hyperplasias progressing to endometrial adenocarcinomas, namely, atypical endometrial hyperplasia (1/8 and 0/8 cases, resp.). None of the positive cases in the series, whether hyperplastic or neoplastic, demonstrated cytological evidence of HPV infection. There was no relation between HPV-positive cases and squamous differentiation, depth of myometrial invasion, lymphatic involvement, lymphocytic response, patients' age, or prognosis.Conclusion. It appears that the presence of HPV in the endometrium, as detected by PCR, does not play any role in the initiation or prognosis of endometrial adenocarcinoma.

Download Full-text